In a world where 1 in 5 liver transplant patients dies waiting, OrganOx isn't just preserving organs—it's rewriting the rules of transplantation. Their normothermic perfusion tech turns a 4-hour organ viability window into 24 hours, creating a logistical revolution in a $20B global transplant market.

"They're not selling a device—they're selling time. In organ transplantation, time isn't money. It's life."

The tech stack reveals sophistication: Tailwind CSS and Bootstrap for performance, PWA for field deployment, HSTS for security—this isn't a biotech with a website slapped together. Every choice screams 'enterprise-ready.' The 8,520 monthly visits seem modest until you realize these aren't consumers—they're transplant surgeons, hospital CFOs, and procurement specialists. This is a B2B2C model where the end-user (patient) is disconnected from the buyer (hospital).

• Normothermic perfusion extends liver preservation from 4 to 24 hours
• Series C funding from Novo Holdings signals commercial readiness
• Dual-market strategy: UK/EU + North America with dedicated SVPs
• High-value keywords dominate search (brand + product-specific)
• Enterprise-grade tech stack for clinical environments